A Study of Barrett's Esophagus Patients to Investigate Quality of Life and Fear of Cancer, and Optimize a Risk Model Based on Biomarkers and New Technologies to Better Predict the Development of Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-07-31

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study serves, in part, to prepare for a future large cohort study. The goal of the study is:

1. The collection of various tissue samples (blood, biopsies and "esophageal brushes") and their analysis.
2. To set up standardized methods for different genetic analyses (DNA-FISH and so-called single cell sequencing) on the esophageal tissue samples.
3. Evaluating the quality of life of Barrett's Esophagus patients and the degree of fear of getting cancer.

Patients with a Barrett's Esophagus can participate in the study if they are minimally 18 years old, are capable of giving informed consent (fully understanding what the study entails before giving consent to participate), have Barrett Esophagus and are referred to one of the participating centers due to suspicion of high-grade dysplasia or early esophageal cancer, for which the participant will be evaluated by endoscopic imaging and biopsy.

Study procedures:

* An intake consultation will be planned, wherein the eligibility criteria will be assessed, and participant characteristics will be collected.
* A routine gastroscopy will be planned twice during which several minimally-invasive interventions will be performed: drawing a blood sample, brush cytology during the endoscopy (a brush is used to obtain cells from the surface of the esophagus) and obtaining biopsy samples (small pieces of tissue). Each participant will need to undergo all the interventions.
* Patients will have to complete questionnaires at three time points to assess their quality of life (EQ-5D-DL questionnaire) and fear of cancer recurrence (Cancer Worry Scale).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Barrett's Esophagus and Esophageal Adenocarcinoma, Searching for Reliable Diagnostic RNA Plasma-based Biomarkers

NCT05688176

Esophageal Neoplasms

RECRUITING

Stratifying Risk in Barrett's Esophagus: A Pilot Study for Biomarker-based Patient Management

NCT02075905

Barrett's Esophagus Esophageal Adenocarcinoma Intestinal Metaplasia +1 more

COMPLETED

Preliminary Longitudinal Validation of Biomarkers Predictive of Barrett's Esophagus

NCT00844077

Barrett's Esophagus

COMPLETED

A Minimally-Invasive Sponge on a String Device for Screening for Barrett's Esophagus

NCT02560623

Barrett Esophagus

COMPLETED NA

The Microbiome, Bile Acids, and Notch in Barrett's Esophagus (BE)

NCT05524844

Barrett Esophagus Esophageal Adenocarcinoma

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

More specifically, you will have a standard endoscopy twice during which tissue samples will be taken from the esophagus to check for the severity of the disease. This is part of standard care. If you participate in the study, additional samples will be taken from the esophagus and also from the stomach (a total maximum of 10 samples of 1-2 mm). As a result, the endoscopic examination will take about 10-15 minutes longer than standard. Furthermore, in addition to the tissue samples, cells of the esophageal mucosa will be sampled (through 4 "esophageal brushes") and blood (4 tubes) will also be collected.

For this study, you will be contacted a total of three times. Once for a screening visit and twice for the sample collection described above. The screening and sample collection will take place during the already scheduled treatments and consultations. Afterwards, patient outcomes will be documented for the study until a maximum of 5 years after inclusion. This documentation will take place during the routine follow up so does not require any additional visits for the patients. Additionally you will be asked to complete two short questionnaires on your mobile phone at three time points during the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Barrett's Esophagus Esophageal Adenocarcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Endoscopic brush cytology

Each participant will receive all interventions. A routine endoscopy will be planned during which several minimally invasive interventions will be performed:

drawing a blood sample (standard of care), brush cytology (not standard of care) and biopsies (standard of care) during the endoscopy.

Group Type OTHER

Endoscopic brush cytology

Intervention Type PROCEDURE

A total of four brush samples will be taken during the endoscopy. Other minimally invasive interventions during this study are standard of care.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Endoscopic brush cytology

A total of four brush samples will be taken during the endoscopy. Other minimally invasive interventions during this study are standard of care.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with known BE undergoing endoscopy for possible treatment by EMR or ESD due to suspicion of early esophageal Barrett cancer
* Capable of receiving informed consent and of giving permission
* Age 18 and upward

Exclusion Criteria

* Patients with current known malignancy of the gastrointestinal tract other than the esophageal lesion
* Patients with severe co-morbidity that prohibits endoscopic therapy under sedation or conscious sedation (such as severe cardiac or pulmonary disease)
* Esophageal varices
* Uncontrollable coagulation disorders
* Undergoing chemotherapy or immunotherapy or received chemotherapy \< 6 weeks prior to endoscopy
* Undergoing radiotherapy within the esophageal region or received chemotherapy \< 6 months prior to endoscopy
* WHO score \> 3

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sheila Krishnadath

Role: PRINCIPAL_INVESTIGATOR

Universitair Ziekenhuis Antwerpen (UZA)

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Antwerp

Edegem, Antwerpen, Belgium

Site Status RECRUITING

Sint-Augustinus Hospital (ZAS)

Wilrijk, Antwerpen, Belgium

Site Status RECRUITING